**FR0014000MR3 - Common Stock **

Overall **ERF** gets a fundamental rating of **3** out of 10. We evaluated **ERF** against 7 industry peers in the **Life Sciences Tools & Services** industry. **ERF** has a bad profitability rating. Also its financial health evaluation is rather negative. **ERF** has a correct valuation and a medium growth rate.

ROA (6.26%) VS Industry: 20% outperformed.

2.87

21.58

ROE (13.68%) VS Industry: 40% outperformed.

7.73

34.07

Profit Margin (9.37%) VS Industry: 25% outperformed.

5.29

20.63

Compared to an average industry price book ratio of 2.99, **ERF** is valued rather cheaply

Compared to an average **Enterprise Value to EBITDA** ratio of 21.20, **ERF** is valued rather cheaply. On top of this, **ERF** has a better ratio than **100%** of the companies listed in the same industry.

With a **Price/Earnings Ratio** of **19.19**, **ERF** is valued on the expensive side.

Compared to an average industry **Price/Earning Ratio** of **19.98**, **ERF** is valued in line with its industry peers.

The **Forward Price/Earnings Ratio** of **18.71** indicates a rather expensive current valuation of **ERF**.

When comparing the current price to the book value of **ERF**, we can conclude it is valued correctly. It is trading at **2.52** times its book value.

Price/Earnings (19.19) VS Industry: 60% outperformed.

41.94

7.07

Price/Book (2.52) VS Industry: 66% outperformed.

13.80

1.24

Enterprise Value/ EBITDA (8.25) VS Industry: 100% outperformed.

539.50

8.25

The **Earnings Per Share** has been growing by **35.72%** on average over the past 5 years. This is a very strong growth

The **Earnings Per Share** is expected to decrease by **-5.21%** on average over the next 5 years.

Looking at the last year, **ERF** shows a small growth in **Revenue**. The Revenue has grown by **7.35%** in the last year.

Based on estimates for the next 5 years, **ERF** will show a small growth in **Revenue**. The Revenue will grow by **1.83%** on average per year.

When comparing the EPS growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

Past | Future | ||||||
---|---|---|---|---|---|---|---|

5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |

EPS | 35.72% | 57.76% | -29.82% | -22.57% | -15.98% | -8.43% | -5.21% |

Revenue | 21.5% | 21.12% | 7.35% | 4.61% | 1.76% | 3.58% | 1.83% |

A Current Ratio of **1.33** indicates that **ERF** should not have too much problems paying its short term obligations.

A Quick Ratio of **1.25** indicates that **ERF** should not have too much problems paying its short term obligations.

When comparing the Current Ratio of **ERF** to the average industry Current Ratio of **1.49**, **ERF** is less able to pay its short term obligations than its industry peers.

Compared to an average industry Debt to Equity Ratio of **0.48**, **ERF** is requires more financing than its industry peers. **84%** of its industry peers have a better Debt to Equity Ratio.

Compared to an average industry Altman-Z score of 4.32, **ERF** is in worse financial state than most of its industry peers. **84%** of its industry peers have a better Altman-Z score.

Debt/Equity (0.66) VS Industry: 16% outperformed.

1.00

0.00

Quick Ratio (1.25) VS Industry: 50% outperformed.

0.45

19.50

Current Ratio (1.33) VS Industry: 33% outperformed.

0.74

19.50

Altman-Z (2.92) VS Industry: 16% outperformed.

1.69

26.71

Compared to an average industry **Dividend Yield** of **1.49**, **ERF** pays a bit more dividend than its industry peers.

On average, the dividend of **ERF** grows each year by **51.43%**, which is quite nice.

With a **Yearly Dividend Yield** of **1.49%**, **ERF** has a reasonable but not impressive dividend return.

With a **Dividend Yield** of **1.49**, **ERF** pays less dividend than the S&P500 average, which is at **2.60**.

The **Dividend Rate** of **ERF** has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.

The earnings of **ERF** are negative and hence is the payout ratio. **ERF** will probably not be able to sustain this dividend level.

Dividend Yield (1.49%) VS Industry: 66% outperformed.

0.40

1.82

EPA:ERF (3/29/2023, 9:52:21 AM)**+0.16 (+0.26%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryLife Sciences Tools & Services

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap11.82B

Analysts68.42

Price Target73.51 (19.72%)

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 1.49% |

Dividend Growth(5Y)51.43%

DP-0.06%

Div Incr YearsN/A

Div Non Decr YearsN/A

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

PT rev (1m)-8.11%

PT rev (3m)-12.52%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-5.9%

EPS NY rev (3m)-5.9%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-0.13%

Revenue NY rev (3m)-0.13%

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 19.19 | ||

Fwd PE | 18.71 | ||

P/S | 1.72 | ||

P/FCF | 17.3 | ||

P/OCF | 9.31 | ||

P/B | 2.52 | ||

P/tB | N/A | ||

EV/EBITDA | 8.25 |

EPS(TTM)3.2

EY5.21%

EPS(NY)3.28

Fwd EY5.34%

FCF(TTM)3.55

FCFY5.78%

OCF(TTM)6.59

OCFY10.74%

SpS35.62

BVpS24.4

TBVpS-3.78

PEG (NY)N/A

PEG (5Y)0.54

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 6.26% | ||

ROE | 13.68% | ||

ROIC | 11.73% | ||

ROICexc | 12.86% | ||

ROICexgc | 46.3% | ||

OM | 18.39% | ||

PM | 9.37% | ||

GM | 25.13% |

ROICexgc(3y)42.91%

ROICexcg growth 3Y20.47%

ROICexcg growth 5Y4.83%

ROICexc(3y)12.04%

ROICexc growth 3Y31.18%

ROICexc growth 5Y8.68%

OM growth 3Y16.76%

OM growth 5Y9.23%

PM growth 3Y33.94%

PM growth 5Y15.35%

GM growth 3Y14.14%

GM growth 5Y8.41%

F-Score3

Asset Turnover0.67

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.66 | ||

Debt/FCF | 4.9 | ||

Debt/EBITDA | 1.91 | ||

Cap/Depr | 120.5% | ||

Profit Quality | 106.32% | ||

Current Ratio | 1.33 | ||

Quick Ratio | 1.25 | ||

Altman-Z | 2.92 |

F-Score3

WACC6.74%

ROIC/WACC6.87

Cap/Depr(3y)82.57%

Cap/Depr(5y)96.41%

Profit Quality(3y)159.26%

Profit Quality(5y)133.79%

Growth

EPS 1Y-29.82%

EPS 3Y57.76%

EPS 5Y35.72%

EPS growth Q2Q-26.4%

EPS Next Y-22.57%

EPS Next 2Y-15.98%

EPS Next 3Y-8.43%

EPS Next 5Y-5.21%

Revenue growth 1Y7.35%

Revenue growth 3Y21.12%

Revenue growth 5Y21.5%

Revenue growth Q2Q4.25%

Revenue Next Year4.61%

Revenue Next 2Y1.76%

Revenue Next 3Y3.58%

Revenue Next 5Y1.83%

EBIT growth 1Y-17.36%

EBIT growth 3Y41.42%

EBIT growth 5Y32.72%

EBIT Next Year17.93%

EBIT Next 3Y5.94%

EBIT Next 5Y6.11%

FCF growth 1Y50.16%

FCF growth 3Y76.72%

FCF growth 5Y41.9%

OCF growth 1Y42.52%

OCF growth 3Y40.54%

OCF growth 5Y32.35%

*Find stocks with similar Fundamental rating on the EuroNext*

*Find the competitors with the best fundamentals on the EuroNext*

*Find the competitors with the best valuation on the EuroNext*

*Find the competitors with the best dividend on the EuroNext*